Great work as usual.
I would say the following list of diseases are potentially just the tip of the iceberg:
I would also suggest with our supply agreements with Bene and the complexity of the PPS molecule being copied it is IMHO unlikely that a bio-similar will be approved for use by the FDA for quite a while.
- OA
- CHIK-V
- RRV
- MPS
- HEART FAILURE
- ARDS
Not to mention the other drugs PAR are investigating for repurposing that we haven’t heard anything about.
My shares are locked away for the next 5 - 10 years.
iPPS and the not so Looney comparison, page-4
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.010(4.17%) |
Mkt cap ! $80.48M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 22.5¢ | $167.1K | 714.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 120730 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 49999 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |